TRPC5 [TRP (transient receptor potential) canonical (or classical) 5] is a widely expressed mammalian homologue of Drosophila TRP, forming a calcium-and sodium-permeable channel in the plasma membrane either as a homomultimer or heteromultimer with other proteins (e.g. TRPC1). Although several factors are known to stimulate the channel, understanding of its endogenous activators and functions is limited. This paper provides a brief and focused review of our latest findings that show that TRPC5 is a sensor of important signalling phospholipids, including lysophosphatidylcholine and sphingosine 1-phosphate, acting extracellularly or intracellularly. Underlying mechanisms of action and biological relevance are discussed.
Introduction
Calcium is the primary second messenger, profoundly influencing most cellular processes [1] . Within this context it is expected that calcium entry has pivotal roles. A well-established set of entry channels is those that are triggered to open by membrane depolarization; it includes the L-type voltage-gated calcium channel, which provides calcium for contraction of muscle, is involved in neurotransmitter release and secretion, is the target for the anti-hypertensive and anti-arrhythmic calcium antagonist drugs and drives the expression of a subset of genes [2] [3] [4] . However, evidence has also emerged suggesting other types of calcium channels with distinct pharmacology and function. Although these may be modulated by membrane potential, a membrane potential change is not the primary trigger for activation. Instead, the channels are activated by chemical signals. A significant fraction of the calcium channels would now seem to be explained by homologues of the Drosophila TRP (transient receptor potential) [5] [6] [7] [8] .
Mammals have at least 25 homologues of TRP [5, 9] . Of these, seven are subclassified (according to amino acid sequence similarity) as TRPC [TRP canonical (or classical)], inferring the closest homology to Drosophila TRP. Although mRNA from the TRPC2 gene is present in humans, human TRPC2 is considered to be a pseudogene, the mRNA containing premature termination codons. The other human TRPC genes are, however, expressed as proteins. Based on amino acid sequence they are subclustered into TRPC1/ TRPC4/TRPC5 and TRPC3/TRPC6/TRPC7. This clustering would also seem to be relevant functionally because the channels can form not only as homomultimeric assemblies of a TRPC but heteromultimeric assemblies of TRPC1, TRPC4 and TRPC5, or TRPC3, TRPC6 and TRPC7 [10, 11] . However, complexities are envisaged, with TRPC3 having capability to interact with TRPC5 if TRPC1 is present [12] . Interactions with other types of TRPs may also occur. For example, TRPC1 interacts with TRPP2 (TRP polycystin 2) and both are reported to contribute to store-operated calcium entry in smooth muscle (reviewed in [7] ). TRPC1 is something of an oddball among the TRPCs because it almost certainly does not form a channel on its own. It is however readily able to assemble with TRPC5 [11, 13] .
Functions of TRPCs have started to emerge, and include regulation of myogenic tone, growth cone extension and turning, and cell proliferation [14] [15] [16] . Contributions to receptor-operated calcium entry have also been suggested [17] ; 'receptor-operated' in this context means that agonist binding to a G-protein-coupled receptor leads to activation of the channel, contrasting with the direct ATP activation of P2X purinergic receptors, for example.
Although significant progress has been made, we feel that understanding of the roles and importance of TRPCs has been hampered by limited knowledge of their endogenous activators. We were also influenced by evidence of versatility in TRP channel activation from studies of TRPC7, TRPV4 (TRP vanilloid 4) and TRPM8 (TRP melastatin 8), and our studies of TRPC5 ( [18] and references therein). Within a single cell expressing TRPC5, activation occurs in response to a multiplicity of signals, albeit with differing efficacies: passive store depletion, muscarinic receptor activation, lanthanide ions or elevated intracellular calcium levels [18] . We reasoned that this list might be greater, and that by finding further activators we might be better able to understand the channel's functions in native systems. Furthermore, we had detected endogenous expression of TRPC5 and TRPC1 in human blood vessels, and functions relating to vascular adaptation were becoming apparent [11, 19] . In such a context, activation by thapsigargin and lanthanides, for example, did not appear especially relevant.
Activation by LPC (lysophosphatidylcholine)
Unlike TRPC1, TRPC5 readily forms functional ion channels when expressed alone. It displays a distinctive currentvoltage relationship (I-V) in electrophysiological experiments [13, 18] , a powerful technical advantage enabling distinction of TRPC5 from endogenous cationic channels. We have therefore used TRPC5 as a starting point for discovering more about endogenous ligands for TRPCs. A small-scale screen was developed using calcium measurement in HEK-293 cells (human embryonic kidney cells) stably expressing human TRPC5 under a tetracycline-dependent promoter. In this system, control (no TRPC5) and induced (TRPC5) cells are compared directly at the same passage number. No functional TRPC5 is evident in the control cells. Positive hits for novel activators were subsequently tested by patchclamp electrophysiology, enabling confirmation of TRPC5 activation by observation of the signature I-V. Unless indicated, data described in this section were published in [20] .
Based on the finding that TRPC1 and TRPC5 are present in proliferating vascular smooth-muscle cells as well as those of the intima of the aged and diseased saphenous vein [19] , we considered that TRPC5 might be activated by chemicals associated with vascular disease. The most prominent vascular disease is atherosclerosis, with much already known about the chemical composition of the plaques. A plaque element and major risk factor in atherosclerosis is oxLDL (oxidized low-density lipoprotein). oxLDL has many components, but the most dominant is LPC [21] . Early on, our TRPC5 screen identified LPC as a novel and powerful activator of TRPC5 [20] .
There is progress towards understanding the mechanism of TRPC5 activation by LPC [20] . One important consideration is whether the data are an artefact due to a detergent effect of LPC on the lipid bilayer. This is not the case, however, because cells without tetracycline induction did not respond to LPC concentrations that activate TRPC5, and cells induced to express TRPM2 also did not respond to LPC. The latter is particularly important because, as for the TRPC5 experiments, cells are exposed to tetracycline and a protein is overexpressed in the plasma membrane, either of which might non-specifically alter bilayer properties, conferring greater sensitivity to a detergent. For comparison and contrast, we showed detergent effects of high concentrations of LPC or Triton X-100 on non-induced control cells; TRPC5 expression reduced, rather than increased, detergentsensitivity. Caution regarding detergent effects is warranted but it is, nevertheless, clear that TRPC5 is activated by LPC, with patch-clamp experiments showing the signature of the TRPC5 I-V. Further evidence against apparent TRPC5 activity arising because of non-specific membrane disruption derives from the observation that arachidonic acid is not effective.
The second important consideration is whether LPC activates TRPC5 via a G-protein-coupled receptor. G-proteincoupled receptors exist for LPC, and TRPC5 is stimulated when carbachol activates muscarinic G-protein-coupled receptor. However, intracellular dialysis with GDP[β-S] (guanosine 5 -[β-thio]triphosphate) failed to affect the LPC response, and yet blocked activation by carbachol. Furthermore, LPC activated TRPC5 in excised outside-out patches without GTP in the pipette, again making it unlikely that LPC activates TRPC5 via a G-protein-coupled receptor.
LPC may also generate free radicals. This does not, however, contribute to LPC activation of TRPC5 because vitamin E, a free radical scavenger, did not affect the LPC response. We have also found that vitamin C, catalase and superoxide dismutase fail to affect the LPC response (E. AL-Shawaf and D.J. Beech, unpublished work).
Therefore it is our hypothesis that LPC is either a direct agonist at the TRPC5 channel or that TRPC5 has specific sensitivity to the structure of the lipid bilayer such that it is activated when the concentration of lipids, such as LPC, increases in the bilayer. The observation that LPC activation of TRPC5 is preserved in the sparse environment of excised membrane patches lends support to this general hypothesis. However, the specifics of the mechanism are unclear. Additional data raise intriguing questions about the underlying mechanism of activation [20] . Although carbon chain length is important for LPC activation, the lack of effect of arachidonic or palmitoleic acids indicates that TRPC5 activation is not a simple consequence of long carbon chain insertion in the bilayer. Instead, similar efficacies of LPC and lysophosphatidylinositol suggest that the side chain needs a bulky but not specific head-group, implying physical distortion of the bilayer is involved. Such a hypothesis is reminiscent of that proposed for LPC activation of the Trek-1 potassium channel [22] . The hypothesis predicts that a coneshaped lipid such as LPC would act only from one side of the bilayer. However, LPC applied to either side of the bilayer activates TRPC5. Thus activation of TRPC5 by LPC is either different from that of Trek-1 or intracellular and extracellular effects of LPC on TRPC5 occur via different mechanisms.
Although we do not yet understand how LPC activates TRPC5, our data rule out a number of mechanisms and suggest a previously unrecognized direct sensing capability of TRPC5 for LPC, a phospholipid with wide-ranging physiological and pathological functions. We suggest that TRPC5 is a lipid ionotropic receptor for extracellular and intracellular LPC [20] .
Biological relevance of TRPC5 activation by LPC
It follows from the above data that native channels containing TRPC5 may be direct sensors of endogenous LPC produced extracellularly via a secreted phospholipase A 2 , or intracellularly via a cytosolic or Ca 2+ -independent phospholipase A 2 . Extracellular LPC has been known for some years to activate non-selective cationic channels in a range of cells and we have observed LPC activation of cationic current in freshly isolated smooth-muscle cells dialysed with
GDP[β-S] ([20] and references therein). Human monocytes show Ca
2+ entry in response to LPC that is independent of G-protein and phospholipase C signalling and dependent on LPC carbon chain length [23] , features reminiscent of TRPC5 activation by LPC. It is also observed that intracellular LPC and LPI (lysophosphatidylinositol) activate cationic channels with a conductance similar to that of TRPC5-TRPC1 heteromultimeric channels [24] . However, we do not yet know if any of these responses depend on TRPC5 or a related protein.
Store depletion or agonists at G-protein-coupled receptors elevate intracellular LPC, which raises the possibility that association of TRPC5 with store-and receptor-operated Ca 2+ -entry mechanisms is a reflection of the channel's sensitivity to LPC. Consistent with this idea we recently reported that antibody to TRPC5 suppresses store-operated Ca 2+ entry in arterioles [25] . Whether TRPC5 contributes to such Ca 2+ -entry mechanisms will presumably depend on the concentration of LPC generated in the vicinity of the channel as well as cofactors that facilitate or inhibit channel activity. It should be noted that some store-operated channels, such as the CRAC (calcium-release-activated calcium channel) of lymphocytes, probably do not involve TRPC5.
Activation by S1P (sphingosine 1-phosphate)
As part of the screen for TRPC5 activators we also tested S1P. Like LPC, S1P is present in oxLDL, although greater levels occur in the HDL (high-density lipoprotein) fraction, which is protective in atherosclerosis. We have found that S1P activates TRPC5 [11] . Intriguingly, and paralleling the dual signalling function of S1P, TRPC5 is a bipolar target, showing activation by extracellular and intracellular S1P. Although this is as for LPC, the mechanism of the extracellular effect is different. Unless indicated, data described in this section were published in [11] .
The extracellular effect of S1P on TRPC5 occurs via Gprotein-coupled receptors. S1P receptors are expressed in HEK-293 cells. The effect of S1P on TRPC5 is blocked by GDP[β-S] or pertussis toxin, the latter being an inhibitor of G i/o proteins. Carbachol activation of TRPC5, by contrast, is not pertussis toxin-sensitive, showing that two types of G-protein couple with TRPC5. The signalling cascade after the G-protein is unknown. The S1P effect is suppressed by a phospholipase C inhibitor, but diacylglycerol, protein kinase C and IP 3 (inositol trisphosphate) are not strong candidates for the transduction signal (reviewed in [26] ). S1P has no effect on TRPC5 studied in excised outside-out patches without GTP in the pipette. Therefore, unlike LPC, S1P has no direct extracellular effect on TRPC5. S1P applied to the intracellular surface activates TRPC5 in inside-out membrane patches. This could be an important observation because S1P is generated inside and outside of cells, and has targets on both sides of the membrane. Few intracellular targets for S1P have been identified, however. TRPC5 is a new intracellular target for S1P but the physiological
importance is yet to be demonstrated. Potentially, intracellular S1P acts directly on TRPC5, conferring on TRPC5 the property of ionotropic receptor for intracellular S1P.
Biological relevance of TRPC5 activation by S1P
S1P has emerged as a major endogenous signalling phospholipid. There has been particular interest in its roles in the cardiovascular system where it evokes arterial constriction, modulates smooth-muscle cell migration, accumulates in atherosclerotic lesions, slows pacemaker activity in the heart and plays a role in ischaemic preconditioning (see references in [11] ). Discovery of a role for TRPC5 in growth cone extension [16] prompted us to consider whether S1P activation of TRPC might be important in smooth-muscle cell motility. Because vascular smooth-muscle cells express TRPC1 as well as TRPC5 (and there is no evidence for TRPC5 homomultimeric channels in these cells) it was important to find that S1P also activates the TRPC5-TRPC1 heteromultimeric channel [11] .
Cell motility was explored using a linear wound assay in a planar culture of human saphenous vein smooth-muscle cells. S1P enhanced cellular re-population of the wound and this effect was suppressed by 2-aminoethoxydiphenyl borate (a non-specific blocker of TRPC5), E3-targeted anti-TRPC5 antibody or a dominant-negative ion-pore mutant of TRPC5. There is thus strong evidence that S1P evokes migration of vascular smooth-muscle cells through a mechanism requiring ion permeation through a plasma membrane channel that includes TRPC5 as a subunit. This effect seems to occur almost exclusively via the extracellular S1P action because it is strongly suppressed by pertussis toxin. S1P has been suggested to be a signal coupling depleted calcium stores with channels [27] . Extracellular S1P and carbachol also elevate intracellular levels of S1P. Therefore, as with LPC, S1P could be an intracellular messenger contributing to TRPC5 activation by store depletion or receptor activation.
Conclusions
We believe our recent findings [11, 20] have started the process of bringing TRPC5 within the general concept of TRP channels as lipid ionotropic receptors. We also develop the concept of TRPCs as ionotropic receptors for intracellular lipids. Although direct supporting evidence is lacking, the controversial or enigmatic store-and receptor-operated properties of these channels may be one manifestation of their lipid-sensing capabilities.
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